|
1
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Gruppo Italiano Malattie Ematologiche dell'Adulto;
German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance
Leukemia: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tallman MS and Altman JK: How I treat
acute promyelocytic leukemia. Blood. 114:5126–5135. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Donnell MR, Tallman MS, Abboud CN,
Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE,
Damon LE, et al: National Comprehensive Cancer Network: Acute
myeloid leukemia, version 2.2013. J Natl Compr Canc Netw.
11:1047–1055. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mandelli F, Diverio D, Avvisati G, Luciano
A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni
G, et al: Molecular remission in PML/RAR alpha-positive acute
promyelocytic leukemia by combined all-trans retinoic acid and
idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche
Maligne dell'Adulto and Associazione Italiana di Ematologia ed
Oncologia Pediatrica Cooperative Groups. Blood. 90:1014–1021.
1997.PubMed/NCBI
|
|
5
|
Rodeghiero F, Avvisati G, Castaman G,
Barbui T and Mandelli F: Early deaths and anti-hemorrhagic
treatments in acute promyelocytic leukemia. A GIMEMA retrospective
study in 268 consecutive patients. Blood. 75:2112–2117.
1990.PubMed/NCBI
|
|
6
|
Miller WH Jr, Kakizuka A, Frankel SR,
Warrell RP Jr, DeBlasio A, Levine K, Evans RM and Dmitrovsky E:
Reverse transcription polymerase chain reaction for the rearranged
retinoic acid receptor alpha clarifies diagnosis and detects
minimal residual disease in acute promyelocytic leukemia. Proc Natl
Acad Sci USA. 89:2694–2698. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu
YM, Li JM, Tang W, Zhao WL, Wu W, et al: Long-term efficacy and
safety of all-trans retinoic acid/arsenic trioxide-based therapy in
newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci
USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yanada M, Matsushita T, Asou N, Kishimoto
Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F,
et al: Severe hemorrhagic complications during remission induction
therapy for acute promyelocytic leukemia: Incidence, risk factors,
and influence on outcome. Eur J Haematol. 78:213–219. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iland H, Bradstock K, Seymour J, Hertzberg
M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge
S, et al: Australasian Leukaemia and Lymphoma Group: Results of the
APML3 trial incorporating all-trans-retinoic acid and idarubicin in
both induction and consolidation as initial therapy for patients
with acute promyelocytic leukemia. Haematologica. 97:227–234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park JH, Qiao B, Panageas KS, Schymura MJ,
Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM and Tallman
MS: Early death rate in acute promyelocytic leukemia remains high
despite all-trans retinoic acid. Blood. 118:1248–1254. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Kantarjian H, Wang H, Cortes J and
Ravandi F: Acute promyelocytic leukemia: A population-based study
on incidence and survival in the United States, 1975–2008. Cancer.
118:5811–5818. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lehmann S, Ravn A, Carlsson L, Antunovic
P, Deneberg S, Möllgård L, Derolf AR, Stockelberg D, Tidefelt U,
Wahlin A, et al: Continuing high early death rate in acute
promyelocytic leukemia: A population-based report from the Swedish
Adult Acute Leukemia Registry. Leukemia. 25:1128–1134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Frankel SR, Eardley A, Lauwers G, Weiss M
and Warrell RP: The ‘retinoic acid syndrome’ in acute promyelocytic
leukemia. Ann Intern Med. 117:292–296. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sanz MA, Lo Coco F, Martín G, Avvisati G,
Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD,
Liso V, et al: Definition of relapse risk and role of
nonanthracycline drugs for consolidation in patients with acute
promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA
cooperative groups. Blood. 96:1247–1253. 2000.PubMed/NCBI
|
|
15
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events. Version 4.03. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdfJune
14–2010
|
|
16
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: International Working Group for Diagnosis,
Standardization of Response Criteria, Treatment Outcomes, and
Reporting Standards for Therapeutic Trials in Acute Myeloid
Leukemia: Revised recommendations of the international working
group for diagnosis, standardization of response criteria,
treatment outcomes, and reporting standards for therapeutic trials
in acute myeloid leukemia. J Clin Oncol. 21:4642–4649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Botton S, Chevret S, Coiteux V, Dombret
H, Sanz M, Miguel San J, Caillot D, Vekhoff A, Gardembas M,
Stamatoulas A, et al: European APL group: Early onset of
chemotherapy can reduce the incidence of ATRA syndrome in newly
diagnosed acute promyelocytic leukemia (APL) with low white blood
cell counts: Results from APL 93 trial. Leukemia. 17:339–342. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Montesinos P, Bergua JM, Vellenga E, Rayón
C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, et
al: Differentiation syndrome in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and anthracycline
chemotherapy: characteristics, outcome, and prognostic factors.
Blood. 113:775–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tallman MS and Manji GA: Don't just stand
there, do something: strategies for the prevention of early death
in acute promyelocytic leukemia: a commentary. Blood Cells Mol Dis.
46:173–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
